As a patient-reported outcome, pain is a major patient-relevant efficacy parameter in clinical practice in Ankylosing Spondylitis (AS). This study will therefore monitor overall neck, back and hip pain on a continuous basis. It will be recommended that NSAID should be tapered if the patient reports an improvement in back pain or a level below a certain threshold. It is anticipated that the results of this study may provide guidance for the systematic adjustment of concomitant NSAID treatment in AS patients based on their initial response to Secukinumab, thereby leading to optimization of the therapeutic strategy with Secukinumab.